Seeking Alpha

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary...

ACADIA Pharmaceuticals (ACAD) announces Pimavanserin has met its primary and key secondary endpoints in its Phase III Parkinson's Psychosis Trial. Shares are halted in premarket trading. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|